Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma

Published:2019-01-21 Issue:2 Volume:36 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Ngamphaiboon Nuttapong^ORCID,Chureemas Teeranuch,Siripoon Teerada,Arsa Lalida,Trachu Narumol,Jiarpinitnun Chuleeporn,Pattaranutaporn Poompis,Sirachainan Ekaphop,Larbcharoensub Noppadol

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s12032-018-1241-1/fulltext.html

Reference33 articles.

1. Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Semin Radiat Oncol. 2018;28(1):12–6. https://doi.org/10.1016/j.semradonc.2017.08.009 .

2. Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018. https://doi.org/10.1016/j.semcancer.2018.01.008 .

3. Qi X, Jia B, Zhao X, Yu D. Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. OncoTargets Therapy. 2017;10:5745–54. https://doi.org/10.2147/ott.S148182 .

4. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65. https://doi.org/10.1016/S1470-2045(16)30066-3 .

5. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45. https://doi.org/10.1200/JCO.2016.68.1478 .

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer;Biomolecules;2024-07-30

2. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics;Indian Journal of Otolaryngology and Head & Neck Surgery;2024-03-10

3. Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer;Biomedicines;2024-02-10

4. Prognostic role of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: An institutional experience from India;Pathology - Research and Practice;2024-01

5. Programmed Cell Death Ligand 1 Immunoexpression in Head and Neck Squamous Cell Carcinoma: A Narrative Review of Considerations for the Histopathologist;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024